Cargando…

Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis

BACKGROUND: Olanzapine has been reported to be an effective antiemetic in patients receiving carboplatin-based chemotherapy. However, the efficacy of a neurokinin-1 receptor antagonist (NK(1)RA) added to olanzapine, a 5-hydroxytryptamine-3 receptor antagonist (5-HT(3)RA), and dexamethasone (DEX) has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamamoto, Senri, Iihara, Hirotoshi, Uozumi, Ryuji, Kawazoe, Hitoshi, Tanaka, Kazuki, Fujita, Yukiyoshi, Abe, Masakazu, Imai, Hisao, Karayama, Masato, Hayasaki, Yoh, Hirose, Chiemi, Suda, Takafumi, Nakamura, Kazuto, Suzuki, Akio, Ohno, Yasushi, Morishige, Ken-ichirou, Inui, Naoki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941806/ https://www.ncbi.nlm.nih.gov/pubmed/35321690 http://dx.doi.org/10.1186/s12885-022-09392-9

Ejemplares similares

Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials
por: Yamamoto, Senri, et al.
Publicado: (2021)

Association of 5-Hydroxytryptamine 3 Receptor Antagonists With the Prognosis of Liver Failure
por: Chen, Yuting, et al.
Publicado: (2021)

Study protocol for an open-label, single-arm, multicentre phase II trial to evaluate the efficacy and safety of combined triplet therapy and olanzapine for prevention of carboplatin-induced nausea and vomiting in gynaecological cancer patients
por: Iihara, Hirotoshi, et al.
Publicado: (2019)

Neurokinin 1 Receptor Antagonists for Pruritus
por: Alam, Majid, et al.
Publicado: (2021)

The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694.
por: Bermudez, J., et al.
Publicado: (1988)

Neurokinin-1 Receptor Antagonists against Hepatoblastoma
por: Muñoz, Miguel, et al.
Publicado: (2019)

The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting
por: Palli, Swetha Rao, et al.
Publicado: (2015)

Effective treatment with combination of peripheral 5‐hydroxytryptamine synthetic inhibitor and 5‐hydroxytryptamine 2 receptor antagonist on glucocorticoid‐induced whole‐body insulin resistance with hyperglycemia
por: Ma, Shaoxin, et al.
Publicado: (2016)

Treating hot flushes with a neurokinin 3 receptor antagonist
por: Prague, Julia K., et al.
Publicado: (2017)

Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal
por: Gompel, Anne, et al.
Publicado: (2023)

Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms
por: Pinkerton, JoAnn V, et al.
Publicado: (2023)

The Effect of 5-Hydroxytryptamine Receptor Antagonist in Preventing Pain/Limb Shrinkage Reaction Associated with Rocuronium Injection
por: He, Qixiong, et al.
Publicado: (2018)

Two cases of nintedanib-induced diarrhoea treated using a 5-hydroxytryptamine type 3 receptor antagonist
por: Arai, Toru, et al.
Publicado: (2022)

Neurokinin-1 Receptor Antagonist Treatment in Polymicrobial Sepsis: Molecular Insights
por: Hegde, Akhil, et al.
Publicado: (2010)

Neurokinin-1 receptor antagonists: A new revolution in antiretroviral treatment?
por: Grewal, Udhayvir Singh
Publicado: (2016)

The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?
por: Muñoz, Miguel, et al.
Publicado: (2020)

Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1–4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy
por: Minatogawa, Hiroko, et al.
Publicado: (2020)

Efficacy of Olanzapine 5 mg versus 10 mg for the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving High Emetic Risk Chemotherapy without Neurokinin-1 Receptor Antagonist
por: Sukauichai, Sitthi, et al.
Publicado: (2022)

Association between the Co-administration of Histamine H(2) Receptor Antagonists and the Effectiveness of Capecitabine in Patients with Colorectal Cancer: Propensity Score Analysis
por: Yamazaki, Tomoko, et al.
Publicado: (2022)

The Neurokinin 1 Receptor Antagonist, Ezlopitant, Reduces Appetitive Responding for Sucrose and Ethanol
por: Steensland, Pia, et al.
Publicado: (2010)

Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting
por: Navari, Rudolph M, et al.
Publicado: (2018)

Crystal structures of the human neurokinin 1 receptor in complex with clinically used antagonists
por: Schöppe, Jendrik, et al.
Publicado: (2019)

Neurokinin receptor antagonists as potential non-hormonal treatments for vasomotor symptoms of menopause
por: Conklin, Melissa, et al.
Publicado: (2023)

Novel Treatment of Ventilator Dyssynchrony From Central Alveolar Hypoventilation Syndrome Utilizing Scheduled 5-Hydroxytryptamine-3 Receptor Antagonist
por: Malkoc, Aldin, et al.
Publicado: (2022)

Neurokinin-1 Receptor Antagonists as Antitumor Drugs in Gastrointestinal Cancer: A New Approach
por: Muñoz, Miguel, et al.
Publicado: (2016)

Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK(1)) receptor antagonists
por: Bošnjak, Snežana M., et al.
Publicado: (2017)

Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men
por: Anderson, Richard A, et al.
Publicado: (2020)

Neurokinin 3 Receptor Antagonists Do Not Increase FSH or Estradiol Secretion in Menopausal Women
por: Prague, Julia K, et al.
Publicado: (2019)

In silico screening of neurokinin receptor antagonists as a therapeutic strategy for neuroinflammation in Alzheimer’s disease
por: Satarker, Sairaj, et al.
Publicado: (2021)

Neurokinin-1 Receptor Antagonists as a Potential Novel Therapeutic Option for Osteosarcoma Patients
por: Robinson, Prema, et al.
Publicado: (2023)

Comparative effectiveness of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a network meta-analysis of randomized controlled studies
por: Rokkas, Theodore, et al.
Publicado: (2021)

5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia
por: Pozhidaev, Ivan V., et al.
Publicado: (2020)

Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II)
por: Hoveyda, Hamid R., et al.
Publicado: (2015)

Antagonist of the neurokinin-1 receptor curbs neuroinflammation in ex vivo and in vitro models of Lyme neuroborreliosis
por: Martinez, Alejandra N., et al.
Publicado: (2015)

Role of fosaprepitant, a neurokinin Type 1 receptor antagonist, in morphine-induced antinociception in rats
por: Prasoon, Pranav, et al.
Publicado: (2016)

Evaluation of the Antinociceptive Effect of Maropitant, a Neurokinin-1 Receptor Antagonist, in Cats Undergoing Ovariohysterectomy
por: Corrêa, Janaina M. X., et al.
Publicado: (2019)

Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome
por: Fraser, Graeme L, et al.
Publicado: (2021)

Neurokinin-1 receptor antagonists for postoperative nausea and vomiting: a systematic review and meta-analysis
por: Murakami, Chiaki, et al.
Publicado: (2020)

The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant
por: Coveñas, Rafael, et al.
Publicado: (2023)

Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials
por: Zheng, Yongping, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_biccocfo2buduj4f852h9dped8